These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30243754)

  • 1. Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer.
    Cunningham JJ; Brown JS; Gatenby RA; Staňková K
    J Theor Biol; 2018 Dec; 459():67-78. PubMed ID: 30243754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.
    Zhang J; Cunningham JJ; Brown JS; Gatenby RA
    Nat Commun; 2017 Nov; 8(1):1816. PubMed ID: 29180633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
    Davies RS; Smith C; Button MR; Tanguay J; Barber J; Palaniappan N; Staffurth J; Lester JF
    Anticancer Res; 2015 Oct; 35(10):5615-21. PubMed ID: 26408734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ; Zhang J
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.
    Cunningham J; Thuijsman F; Peeters R; Viossat Y; Brown J; Gatenby R; Staňková K
    PLoS One; 2020; 15(12):e0243386. PubMed ID: 33290430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.
    Norum J; Nieder C
    Pharmacoeconomics; 2017 Dec; 35(12):1223-1236. PubMed ID: 28756597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
    Elkon JM; Millett RL; Millado KF; Lin J
    Expert Opin Pharmacother; 2018 Apr; 19(5):507-509. PubMed ID: 29494266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapeutic options in metastatic castration-resistant prostate cancer.
    Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
    Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
    Lin J; Patel SA; Sama AR; Hoffman-Censits JH; Kennedy B; Kilpatrick D; Ye Z; Yang H; Mu Z; Leiby B; Lewis N; Cristofanilli M; Kelly WK
    Oncologist; 2016 Nov; 21(11):1296-1297e. PubMed ID: 28178640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
    Friedlander TW; Graff JN; Zejnullahu K; Anantharaman A; Zhang L; Paz R; Premasekharan G; Russell C; Huang Y; Kim W; Aggarwal RR; Lin AM; Fong L; Alumkal JJ; Beer TM; Sharifi N; Alyamani M; Dittamore R; Small EJ; Paris PL; Ryan CJ
    Clin Genitourin Cancer; 2017 Dec; 15(6):733-741.e1. PubMed ID: 28655452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy.
    West JB; Dinh MN; Brown JS; Zhang J; Anderson AR; Gatenby RA
    Clin Cancer Res; 2019 Jul; 25(14):4413-4421. PubMed ID: 30992299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
    Ma H; Zhu G; Wan B; Wu PJ; Wang JY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 46(4):653-6. PubMed ID: 25131489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
    Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
    BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.